Search Results - "WEIDEN, Peter J"

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial by Lysaker, Paul H, Weiden, Peter J, Sun, Xiaowu, O'Sullivan, Amy K, McEvoy, Joseph P

“…Abstract Background Impaired insight poses a challenge in the treatment of patients with schizophrenia because of its potential to jeopardize therapeutic…”
Get full text

Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia by Achtyes, Eric, Simmons, Adam, Skabeev, Anna, Levy, Nikki, Jiang, Ying, Marcy, Patricia, Weiden, Peter J

“…Despite the availability of numerous antipsychotic medications, many patients with schizophrenia continue to experience side effects that contribute to the…”
Get full text

Obesity as a risk factor for antipsychotic noncompliance by Weiden, Peter J, Mackell, Joan A, McDonnell, Diana D

“…Objective: Weight gain is a common side effect of antipsychotic medications and is of particular concern with most of the newer “atypical” antipsychotics. It…”
Get full text

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey by Bessonova, Leona, Velligan, Dawn I, Weiden, Peter J, O'Sullivan, Amy K, Yarlas, Aaron, Bayliss, Martha, Baranwal, Nishtha, Rychlec, Kaitlin, Carpenter-Conlin, Julia, Doane, Michael J, Sajatovic, Martha

“…Oral antipsychotic (AP) medications are frequently prescribed to people with bipolar I disorder (BD-I). A cross-sectional online survey examined the…”
Get full text

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study by Nasrallah, Henry A, Weiden, Peter J, Walling, David P, Du, Yangchun, Yao, Baiyun, Yagoda, Sergey, Claxton, Amy

“…Abstract Background A randomized, controlled, phase 3b study (ALPINE) evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL)…”
Get full text

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia by McEvoy, Joseph P, Weiden, Peter J, Lysaker, Paul H, Sun, Xiaowu, O'Sullivan, Amy K

“…This post hoc analysis of clinical trial data evaluated long-term, self-reported mental and physical health-related quality of life (HRQoL) scores in…”
Get full text

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study by Citrome, Leslie, Weiden, Peter J, McEvoy, Joseph P, Correll, Christoph U., Cucchiaro, Josephine, Hsu, Jay, Loebel, Antony

“…To evaluate the long-term safety and tolerability of lurasidone in schizophrenia and schizoaffective disorder patients switched to lurasidone. Patients in this…”
Get full text

Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis by Allison, David B., Mentore, Janet L., Heo, Moonseong, Chandler, Linda P., Cappelleri, Joseph C., Infante, Ming C., Weiden, Peter J.

“…OBJECTIVE: The purpose of this study was to estimate and compare the effects of anti­psychotics-both the newer ones and the conventional ones-on body weight…”
Get full text

Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison by Cameron, Chris, PhD, Zummo, Jacqueline, MPH, MBA, Desai, Dharmik N., PharmD, Drake, Christine, BScN, Hutton, Brian, PhD, Kotb, Ahmed, MSc, Weiden, Peter J., MD

“…Abstract Background Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis…”
Get full text

Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone by Weiden, Peter J, Kim, Edward, Bermak, Jason, Turkoz, Ibrahim, Gopal, Srihari, Berwaerts, Joris

“…To evaluate the effect of 1 oral and 2 distinct long-acting injectable (LAI) formulations of the same antipsychotic on times to relapse following medication…”
Get full text

Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic by Yohn, Samantha E, Weiden, Peter J, Felder, Christian C, Stahl, Stephen M

“…Modern interest in muscarinic acetylcholine receptor (mAChR) activators for schizophrenia began in the 1990s when xanomeline, an M /M -preferring mAChR agonist…”
Get full text

Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study by Weiden, Peter J, Breier, Alan, Kavanagh, Sarah, Miller, Andrew C, Brannan, Stephen K, Paul, Steven M

“…To evaluate Positive and Negative Syndrome Scale (PANSS) categorical response rates, time course of response, and symptom subdomains of response with the…”
Get full text

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia by Martin, William F, Correll, Christoph U, Weiden, Peter J, Jiang, Ying, Pathak, Sanjeev, DiPetrillo, Lauren, Silverman, Bernard L, Ehrich, Elliot W

“…Objective:Preclinical evidence and data from a proof-of-concept study in healthy volunteers suggest that samidorphan, an opioid antagonist, mitigates weight…”
Get full text

Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study by Lauriello, John, Claxton, Amy, Du, Yangchun, Weiden, Peter J.

“…OBJECTIVETo describe the long-term safety, tolerability, and symptom trajectory with the long-acting injectable antipsychotic aripiprazole lauroxil (AL) in…”
Get full text

Redefining Medication Adherence in the Treatment of Schizophrenia: How Current Approaches to Adherence Lead to Misinformation and Threaten Therapeutic Relationships by Weiden, Peter J

“…Medication adherence is as much of a problem today as it was 50 years ago. A major barrier to progress is that the definition emphasizes obedience to…”
Get full text

How many treatments before clozapine? medication choices across the spectrum of treatment resistance in schizophrenia by Weiden, Peter J

Get full text

Helping Patients With Mental Illness Get Back to Work by Weiden, Peter J.

Get full text

Understanding Why Muscarinic Receptor Agonists Have Antipsychotic Properties by Weiden, Peter J., Yohn, Samantha, Felder, Christian C.

“…All current antipsychotics have direct dopamine (DA) D2 receptor activity, which is associated with problems such as dysphoria, EPS, or prolactin elevation…”
Get full text

Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia by Jain, Rakesh, Meyer, Jonathan, Wehr, Angela, Rege, Bhaskar, von Moltke, Lisa, Weiden, Peter J

“…One of the challenges with initiating long-acting injectable (LAI) antipsychotic regimens is achieving relevant drug levels quickly. After first injection of…”
Get full text

Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study by Weiden, Peter J, Claxton, Amy, Kunovac, Jelena, Walling, David P, Du, Yangchun, Yao, Baiyun, Yagoda, Sergey, Bidollari, Ilda, Keane, Elizabeth, Cash, Ethan

“…Evaluate efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) with 1-day initiation during hospitalization for acute exacerbation of…”
Get full text